Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

NCT05986864 is registered in ClinicalTrials.gov with Skyline Therapeutics (US) Inc. as lead sponsor.

NCT NCT05986864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05986864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Lead sponsor
Skyline Therapeutics (US) Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 23, 2024
Completion date
January 30, 2027
Enrollment
68 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration